Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$14B
P/E
N/A
Revenue Growth
+15.0%
Gross Margin
N/A
ROE
N/A
About Exact Sciences
Listed on the NASDAQ, Exact Sciences operates as a mid-cap player in the healthcare sector, offering investors focused access to biotech and genomics growth drivers. Cancer screening pioneer with Cologuard and liquid biopsy development. With a $14B market capitalization and no current profitability, the business is characterized by consistent top-line gains, reporting +15% revenue change year-over-year.
Expert Coverage
Unlock Full EXAS Analysis
Expert analysis and coverage for Exact Sciences
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
CRISPR Therapeutics
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.